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ABSTRACT
Background: House dust extract is used in conventional immunotherapy for house dust-mite (HDM) allergic
rhinitis in Japan. However, an alternative administration route is desired. The aims of the present double blind,
placebo-controlled trial were to evaluate the therapeutic efficacy and safety of sublingual immunotherapy
(SLIT) with house dust extract in pediatric patients with HDM allergic rhinitis.
Methods: The study population comprised 31 subjects (21 males and 10 females) aged from 7 to 15 years
old. Twenty patients (the active group) received house dust extract and 11 received placebo via sublingual ad-
ministration. Extract or placebo (1 ml) was administered at 10-fold dilution once weekly for 40 weeks. During
the study period, the subjects recorded their daily nasal symptoms and use (dose and frequency) of other medi-
cations in a nasal allergy diary.
Results: The symptom scores in the active group began to decrease about 24 weeks after initiation of treat-
ment and significant differences between the active and placebo groups were observed after 30 weeks. The
average scores for the last four weeks of the study were significantly lower than those for the first four weeks in
the active group but not in the placebo group. The only local adverse effect was a bitter taste reported by one
patient. There were no other local or systemic adverse effects associated with SLIT.
Conclusions: Our results suggest that SLIT with house dust extract for more than 30 weeks is safe and effec-
tive treatment for HDM allergic rhinitis in children.
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INTRODUCTION
An increased prevalence of allergic rhinitis has been
found worldwide1,2 and the onset age has decreased
in pediatric patients.2 Once allergic rhinitis develops
in childhood, the disease does not remit easily3 and
may impair quality of life and school performance for
many years.4,5 Current therapy for allergic rhinitis in-
cludes allergen avoidance, symptomatic medication,
and immunotherapy. Conventional allergen-specific
immunotherapy via the subcutaneous route (SCIT) is
effective for changing the natural course of allergic
rhinitis and has long-term effects.6-11 However, an al-
ternative administration route is still required since
the SCIT approach requires multiple injections and
frequent visits to a physician’s office, and can have se-
vere systemic adverse effects.12 A safer and simpler
approach is particularly important for pediatric pa-
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Week 4Week 3Week 2Week 1
10 fold10 fold100 fold1000 fold
1.0 ml0.2 ml0.2 ml0.2 mlDay 1
0.4 ml0.4 ml0.4 mlDay 2
0.6 ml0.6 ml0.6 mlDay 3
0.8 ml0.8 ml0.8 mlDay 4
1.0 ml1.0 ml1.0 mlDay 5
Day 6
Day 7
Table 1 Dose and dosing frequency
tients.
Sublingual allergen-specific immunotherapy (SLIT)
may offer a safe and effective alternative administra-
tion route and has attracted particular attention in
Europe. The house dust mite (HDM) is the major al-
lergen in pediatric patients and several randomized
controlled trials of HDM in children have been re-
ported.13-16 Bahçeciler et al.13 treated 15 pediatric pa-
tients with HDM extract for 6 months and showed
that the mean daily doses of intranasal steroids de-
creased in these patients. Ippoliti et al.14 similarly
treated 86 pediatric patients for 6 months and found a
significant reduction in rhinitis scores in the treat-
ment group compared with patients who received a
placebo.
In Japan, SCIT for HDM allergic rhinitis has been
conducted with house dust extract but not with mite
extract for more than 40 years and has been shown to
be effective.17 Although house dust extract contains
not only mite allergens but also other antigens, such
as cockroach, moth and mold, the Japanese Ministry
of Health, Labour, and Welfare has only approved the
use of house dust extract for immunotherapy. The
mite extract widely used in western countries is not
available in Japan. One milliliter of the house dust ex-
tract contains about 7 μg of Der f 1, one of the major
allergens of Dermatophagoides farinae. The concen-
trations of other allergens have not been determined.
To evaluate the efficacy of SLIT, a double-blind pla-
cebo controlled study was conducted in pediatric pa-
tients with HDM allergic rhinitis using the house
dust extract used in Japan.
METHODS
SUBJECTS
The study population comprised 31 subjects (21
males and 10 females) ranging in age from 7 to 15
years old and living in Chiba, Hokkaido, or Akita. The
subjects had a clinical history of HDM allergic rhini-
tis, but were otherwise healthy. Diagnosis of HDM al-
lergic rhinitis was based on clinical history, positive
allergen-specific skin tests (wheal diameter 10
mm) to house dust extract (Torii Pharmaceutical, To-
kyo, Japan), and a serum house dust mite-specific IgE
score 2 on the CAP-radioallergosorbent test (CAP-
RAST, SRL Inc., Tokyo, Japan). Patients who had
been treated with any allergen-specific immunother-
apy (including with house dust) and those with se-
vere or poorly controlled asthma were excluded. The
study was conducted at Chiba University Hospital,
Chiba Children’s Hospital, Hokkaido University Hos-
pital, and Akita University Hospital, in compliance
with the Ethical Guidelines for Clinical Studies and
Good Clinical Practice and the Declaration of Hel-
sinki (2000 revision). The protocol was approved by
the Ethics Committee of each hospital, and written in-
formed consent was obtained from each subject prior
to their participation in the study.
HOUSE DUST EXTRACT
Extracts of house dust (Torii Pharmaceutical: lot
number; ASCY) were used in the study. This extract
contained 5 μgml of Der f 1.
STUDY PROTOCOL
The study was performed as a placebo-controlled,
double-blinded trial. The subjects were randomly allo-
cated into two groups based on a table of random
numbers produced by the Department of Pharmacy
at Chiba University Hospital. An administrator who
was not directly involved in the study was responsible
for group allocation. The patients were randomly
placed into active (treatment) and placebo groups at a
ratio of 2 : 1. A group allocation number was given to
each patient. This information was retained by the ad-
ministrator and a member of the ethical committee
who was also not directly involved in the study. The
numbers were accessed with a key after completion
of the study.
The active group (20 patients) received house dust
extract and the placebo group (11 patients) received
placebo by sublingual administration using the spit
method (Table 1). Following a week for washout be-
fore treatment (Week 0), the dose was escalated over
a period of 3 weeks by administration of an increasing
number of extract or placebo drops at three concen-
trations. Patients received increasing doses from
each vial, beginning with 0.2 ml from a 1000-fold di-
luted vial, and increasing by 0.2 ml per day over 5
days. The vaccine was taken sublingually, kept for 2
min without retention reagent, and then spit out. The
procedure was then repeated with each vial until the
maximum dose (1.0 ml of a 10-fold diluted vial) was
reached, as shown in Table 1. The safety of daily
SLIT administration has been shown, but weekly ad-
ministration was used in this study to minimize the
possibility of serious adverse events. The safety of
weekly administration was confirmed in our previous
study in patients with Japanese cedar pollinosis.18
The maintenance dose was about 20 times higher
than that used in conventional subcutaneous immu-
notherapy. Administration was started in November
December 2006 and the study was completed at the
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Table 2 Severity of nasal symptoms
SeverityParameter
-++++++++++
01-56-1011-21≥21Paroxysmal sneezing
(times/day)
01-56-1011-21≥21Runny nose
(Nose blowing fre-
quency; times/day)
NoneNo oral breath-
ing but nasal 
congestion
Severe nasal 
congestion with 
occasional oral-
breathing
Very severe na-
sal congestion 
with frequent 
oral breathing
Complete con-
gestion, al day
Nasal congestion
Adapted from the Practical Guideline for the Management of Alergic Rhinitis in Japan, 2009.
Placebo Group
n = 9
Active Group
n = 19
9.6 (2.5)9.4 (2.2)Mean age, years (SD)
   2 (22.2)   6 (31.6)Female sex, n (%)
5.3 (0.8)4.7 (1.2)Mite RAST score, mean (SD)
5.3 (2.1)5.9 (2.9)Mean duration of HDM alergic rhinitis, years (SD)
Additional alergic disease, n (%)
   7 (77.8)   8 (42.1)Curent bronchial asthma
   2 (22.2)   5 (26.3)Curent atopic dermatitis
0 (0)  1 (5.3)History of atopic dermatitis
   1 (11.1)  1 (5.3)Curent Japanese cedar polinosis
Table 3 Baseline characteristics of the patients
end of October 2007. Patients visited the hospital just
after the period of dose escalation and once every
three months thereafter. At each visit, physicians
checked intranasal findings, nasal allergy diaries and
adverse events.
SYMPTOM SCORING
During the study period the subjects recorded their
daily nasal symptoms and use (dose and frequency)
of other medications in a nasal allergy diary. Symp-
tom, medication and symptom-medication scores
were obtained from the diary records using the fol-
lowing criteria based on a modified Okuda classifica-
tion (Table 2).19,20 For nasal symptoms, the severity
of paroxysmal sneezing (number of sneezes per day),
runny nose (number of times blowing the nose per
day) and nasal congestion were evaluated on a five-
point scale (0-4): 0, no sensation; 1, mild; 2, moderate;
3, severe; and 4, extremely severe. Episodes of sneez-
ing and nose blowing (rhinorrhea) per day were
rated from 0 to 4: 0, none; 1, 1-5 episodes; 2, 6-10 epi-
sodes; 3, 11-20 episodes; and 4, >21 episodes. The
daily total nasal symptom score was expressed as the
highest score for nasal symptoms. Medication was re-
corded based on drug characteristics and duration of
use, using the following codes21: 1, anti-histamines,
mast cell stabilizers and vasoconstrictors; 2, topical,
ocular or nasal steroids. The medication score and
symptom-medication score (medication + symptom
scores) were calculated for each patient. The symp-
tom and symptom-medication scores were used as
the primary outcome parameter and other criteria
were used as secondary outcome parameters.
STATISTICAL ANALYSIS
After completion of the study, clinical and laboratory
data were analyzed by a biostatistician who had previ-
ously not been involved in the trial. After the analysis
was complete, the allocation identification numbers
for the active and placebo groups were accessed.
Data analysis was performed with two-tailed tests at a
significance level of 5%, using a chi-square test, a
Mann-Whitney U test and a Wilcoxon signed-rank
test in SAS v. 8.02 (Cary, NC, USA).
RESULTS
SUBJECTS
Three subjects were excluded from analysis because
of incomplete allergy diaries. None were excluded
due to adverse effects. Data were analyzed for the re-
maining 28 subjects, who showed full compliance
with the study protocol (Table 3). These subjects in-
cluded 19 in the active group (mean age 9.4 years
old, mite RAST score 4.7, duration of HDM allergic
rhinitis 5.9 years) and 9 in the placebo group (mean
age 9.6 years, mite RAST score 5.3, duration of HDM
Yonekura S et al.
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Fig. 1 The mean scores for paroxysmal sneezing and runny nose in the active group de-
creased after week 24 and were significantly lower than those in the placebo group in 32 and 
35. *p < 0.05 (vs. placebo group, Mann-Whitney U test).
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Fig. 2 The mean score for nasal congestion in the active group decreased after week 20.
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allergic rhinitis 5.3 years). There were no significant
differences in age, sex, mite RAST score and duration
of HDM allergic rhinitis between these two groups.
The active group included 8 patients with current
asthma, 5 with current atopic dermatitis, and 1 with a
history of current atopic dermatitis. The placebo
group included 7 patients with current asthma and 2
with current atopic dermatitis. Each group had 1 pa-
SLIT for Allergic Rhinitis in Children
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Fig. 3 Symptom scores in the active group decreased after week 24 and were significantly 
lower than that in the placebo group in week 32. *p < 0.05 (vs. placebo group, Mann-Whitney 
U test).
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Fig. 4 The mean symptom-medication score decreased after week 24 in the active group.
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tient with current Japanese cedar pollinosis. The
rates and severities of the additional allergic diseases
did not differ significantly between the two groups.
NASAL SYMPTOMS SCORES
The mean nasal symptom scores for each week of the
study are shown in Figure 1, 2. The mean higher
score for paroxysmal sneezing or runny nose (Fig. 1)
Yonekura S et al.
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did not differ between the active and placebo groups
until week 24. After this time, this score decreased
for the active group but not for the placebo group,
and the mean scores were significantly lower in the
active group in weeks 32 and 35. The mean nasal con-
gestion scores (Fig. 2) changed randomly in both
groups until week 20, but decreased thereafter in the
active group.
SYMPTOM AND SYMPTOM-MEDICATION
SCORES
The mean symptom and symptom-medication scores
for each week of the study are shown in Figure 3, 4.
These scores showed similar tendencies. Both were
almost constant throughout the study in the placebo
group, but decreased after week 24 in the active
group. The mean symptom scores were significantly
lower in the active group in week 32. A comparison of
the average scores for week 0-3 (a week of washout
before treatment and the first 3 weeks of treatment)
with those for weeks 37-40 (the final 4 weeks of treat-
ment) is shown in Figure 5. The average symptom
score for weeks 37-40 was significantly lower than
that for weeks 0-3 in the active group, while there was
no significant difference in the placebo group. The av-
erage symptom-medication score for weeks 37-40 was
also lower than that for weeks 0-3 in the active group,
but the difference was not significant. In the placebo
group, the average symptom-medication score did
not decrease significantly over the study period.
IMPROVEMENT OF SYMPTOMS
The average symptom score for weeks 37-40 was
compared with the baseline score (the average score
for weeks 0-3) in each patient. A decrease of more
than 1 point was taken to indicate improvement of
symptoms, and this was found in 33% of patients in
the active group but in 0% in the placebo group (Fig.
6). Similarly, the symptom scores one year after the
end of the trial were compared with those at baseline.
This showed improved symptoms in 16% of patients
in the active group, but in 0% in the placebo group.
EFFECT ON OTHER ALLERGIC DISEASES
Of the 8 and 7 patients with asthma in the active and
placebo groups, respectively, the frequency of
asthma attacks after the trial was reduced in 2 and un-
changed in 6 in the active group, and was reduced in
3 and unchanged in 4 in the placebo group. Of the 5
and 2 patients with atopic dermatitis in the active and
placebo groups, respectively, improvement of symp-
toms occurred in 1 patient in the active group. The
other 6 patients showed no change through the
study. There was no significant difference between
the active group and the placebo group in the thera-
peutic effects on asthma and atopic dermatitis.
ADVERSE EFFECTS
One patient in the active group reported a bitter taste.
There were no other local adverse effects and no se-
vere systemic adverse effects related to the treat-
ment.
DISCUSSION
HDM is the most common allergen in pediatric pa-
tients with allergic rhinitis. Natural remission of the
disease is rare in childhood and the condition carries
over to adulthood in most patients. Allergen-specific
SCIT is the only current therapy that can alter the
natural course, but the treatment has practical incon-
veniences. SLIT has been proposed as an effective al-
ternative, but the efficacy of SLIT in pediatric HDM
allergic rhinitis has yet to be shown based on recent
reviews.22-24 Therefore, we examined the therapeutic
effect of SLIT with house dust extract on pediatric
HDM allergic rhinitis over a period of 10 months in a
placebo-controlled study. This house dust extract is
only available in Japan and contains moth, cockroach
andmold antigens, in addition to mite. Except for Der f,
the concentrations of these antigens are unknown.
The active group had significantly lower symptom
scores compared to the placebo group after treatment
for 30 weeks, and the mean symptom score in the ac-
tive group in the last four weeks of the study was sig-
nificantly lower than that in the first four weeks.
The decrease in the symptom-medication score
was not significant, but the medication score may not
reflect the exact quantity of rescue medicines for al-
lergic rhinitis, since more than half of the patients
had asthma or atopic dermatitis. To evaluate the effi-
cacy of SLIT for asthma and atopic dermatitis, we
chose criteria that did not exclude these complica-
tions. Of the 15 patients with asthma, 2 in the active
group and 3 in the placebo group had a decreased
number of attacks in the treatment period. Of the 6
with atopic dermatitis, only 1 patient in the active
group showed improvement of symptoms. Therefore,
the effects of SLIT on asthma and atopic dermatitis
were unclear.
The results for nasal symptoms obtained in this
study were comparable with those in randomized
studies using standardized mite extracts, based on
meta-analysis by Penagos23 and Calamita.25 One year
after treatment, about half of the patients in the active
group, but none in the placebo group, had improved
nasal symptoms compared to the start of treatment.
To obtain long-term effects, a longer treatment period
may be necessary. The doses of allergen extract used
in this study were about 20 times higher than those
used in conventional SCIT in Japan. However, recent
results of SLIT studies for pollinosis have recom-
mended treatment for more than 18 months with
doses of allergens of more than 100 μg. Further com-
parative studies are needed to assess the ideal doses,
temporal intervals, and vehicles for administration.
SLIT for Allergic Rhinitis in Children
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Fig. 5 The average symptom score for weeks 37-40 (the final 4 weeks of the study) was signifi-
cantly lower than that for weeks 0-3 (a week of washout before treatment and the first 3 weeks of 
treatment) in the active group, whereas there was no significant diference in the placebo group.
p: Wilcoxon signed-rank test.
1.0
1.5
2.0
1.0
2.0
3.0
activeactive placeboplacebo
The average score for week 0-3 The average score for week 37-40
p = 0.03 p = 0.21
Symptom Score Symptom  Medication Score
Score Score p = 0.91p = 0.43
Fig. 6 Based on changes in symptom scores, improvement of symptoms was found in 33% of pa
tients in the active group but in 0% in the placebo group at the end of the trial. At one year after the 
end of the trial, improvement was found in 16% of patients in the active group but in 0% in the pla
cebo group.
active placebo active placebo
50%
0%
100%
50%
0%
100%
At the final of the trial One year later from the trial
Clearly Improved Mildly Improved Slightly Improved No Improvement
33%
16%
Although the current study is preliminary, the results
are encouraging and suggest a need for a new study
that includes a comparison of the effects of house
dust extract with those of a standardized mite extract.
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